Upstream Bio (UPB) Cost of Revenue (2024 - 2026)

Upstream Bio has reported Cost of Revenue for 3 years, with the latest figure at $5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 133.58% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $25.9 million (up 204.77% YoY), and the FY2025 full-year result was $23.0 million, up 249.74% from the prior year.
• Cost of Revenue for Q1 2026 stood at $5.0 million, down from $8.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $10.0 million in Q2 2025, with the low at $351000.0 in Q1 2024.
• Average Cost of Revenue over 3 years is $3.9 million, with a median of $2.5 million recorded in 2025.
• Peak annual rise in Cost of Revenue reached 606.21% in 2025, while the deepest fall reached 16.66% in 2025.
• Tracing UPB's Cost of Revenue over 3 years: stood at $2.8 million in 2024, then soared by 202.25% to $8.3 million in 2025, then tumbled by 40.39% to $5.0 million in 2026.
• The last three Cost of Revenue figures came in at $5.0 million (Q1 2026), $8.3 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.

Peer Comparison